The neo-adjuvant treatment in gastrointestinal stromal tumor.
Gastrointestinal Stromal Tumor (GIST) is a rare intra-abdominal tumor, characterized by a specific histological and immunohistochemical pattern. These tumors affect with higher frequency stomach and small bowel and occur at a median age of 60 years with a slight male predominance. An early stage of GIST often don't cause any symptoms, so most GISTs are diagnosed in later stages of the disease. We report a case of GIST diagnosed only with clinical data and positron emission tomography (PET). We demonstrate the usefulness of neoadjuvant treatment with Imatinib mesylate, a newly developed tyrosine kinase receptor inhibitor. The neoadjuvant treatment with Imatinib reduced the mass size and vascularization, making possible a surgical approach.
Catania
V
V
Department of Surgical Sciences, Advanced Tecnology and Organ Transplant, Policlinico, Cannizzaro Hospital, University of Catania, Catania, Italy. vito.catania@policlinico.unict.it
Consoli
A
A
Cavallaro
A
A
Liardo
R L E
RL
Malaguarnera
M
M
D000368:Aged; D001549:Benzamides; D003131:Combined Modality Therapy; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods*; D010879:Piperazines / Q000627:therapeutic use; D049268:Positron-Emission Tomography / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate